Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TLSA Tiziana Life Sciences PLC

Pre-Market Trading 04-29 07:31:52 EDT

0.7801

-0.0610

-7.25%

High0.8500	Low0.7200	Vol252.82K
Open0.8100	D1 Closing0.8411	Amplitude15.46%
Mkt Cap78.25M	Tradable Cap47.91M	Total Shares100.31M
T/O200.80K	T/O Rate0.41%	Tradable Shares61.41M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TLSA","market":"US","secType":"STK","nameCN":"Tiziana Life Sciences PLC","latestPrice":0.7801,"timestamp":1714161600000,"preClose":0.8411,"halted":0,"volume":252821,"delay":0,"floatShares":61408927,"shares":100307817,"eps":-0.188058,"marketStatus":"Pre-Market Trading","change":-0.061,"latestTime":"04-29 07:31:52 EDT","open":0.81,"high":0.85,"low":0.72,"amount":200800.76088143,"amplitude":0.15456,"askPrice":0.9009,"askSize":100,"bidPrice":0.7801,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.188058,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1714397400000},"marketStatusCode":1,"adr":0,"adrRate":2,"listingDate":1542690000000,"exchange":"NASDAQ","adjPreClose":0.7801,"postHourTrading":{"tag":"盘后","latestPrice":0.7896,"preClose":0.7801,"latestTime":"19:36 EDT","volume":6891,"amount":5357.8198,"timestamp":1714174606796},"volumeRatio":0.25839974722137043},"requestUrl":"/m/hq/s/TLSA","defaultTab":"news","newsList":[{"id":"2430280823","title":"Tiziana Life Sciences’ Intranasal Therapy Shows Promise","url":"https://stock-news.laohu8.com/highlight/detail?id=2430280823","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2430280823?lang=en_us&edition=fundamental","pubTime":"2024-04-25 22:57","pubTimestamp":1714057041,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (US) (TLSA) has released an update. Tiziana Life Sciences announced promising results from their study of intranasal foraluma...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-intranasal-therapy-shows-promise?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-intranasal-therapy-shows-promise?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2430811972","title":"Tiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal Foralumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2430811972","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2430811972?lang=en_us&edition=fundamental","pubTime":"2024-04-25 22:00","pubTimestamp":1714053600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 25, 2024  -- Tiziana Life Sciences, Ltd.  , a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced for the first time, quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab treated patients with non-active secondary progressive multiple sclerosis . White Matter Z-scores are a statistical measure used in neuroimaging studies to assess the integrity or abnormalities in structures of the brain.*EA5 showed a worsening in their White Matter Z-Score at three months du","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/FtrDHJ_OOrnDn6lWq3hU8A--~B/aD00MDQ7dz02MTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e9e16bb2f73219ef8544d38f667bd504","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/FtrDHJ_OOrnDn6lWq3hU8A--~B/aD00MDQ7dz02MTY7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/e9e16bb2f73219ef8544d38f667bd504"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-reports-positive-140000979.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429819687","title":"Tiziana spikes as FDA clears additional patients for expanded access program","url":"https://stock-news.laohu8.com/highlight/detail?id=2429819687","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2429819687?lang=en_us&edition=fundamental","pubTime":"2024-04-23 20:05","pubTimestamp":1713873902,"startTime":"0","endTime":"0","summary":"Shares of Tiziana Life Sciences  rose ~13% premarket Tuesday after the British biotech said that the U.S. FDA has broadened its Expanded Access  Program for the lead candidate foralumab targeted at the brain disorder, multiple sclerosis. Also known as \"compassionate use,\" the FDA's EA program allows patients to receive experimental therapies outside clinical trials in the absence of comparative or adequate alternative therapeutic options.  As for foralumab's EA program targeted at patients with non-active Secondary Progressive Multiple Sclerosis , the regulator has greenlighted an additional 20 individuals, expanding it from 10 to 30. In November, Tiziana  launched a Phase 2a trial for foralumab, an intranasal anti-CD3 monoclonal antibody. The company said those who were not eligible for the trial would be considered for the expanded EA program.    More on Tiziana Life Sciences  Seeking Alpha’s Quant Rating on Tiziana Life Sciences Financial information for Tiziana Life Sciences","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4092395-tiziana-stock-spikes-fda-widens-expanded-access-program","is_publish_highlight":false,"gpt_icon":0},{"id":"2429978585","title":"Tiziana’s MS Drug Shows Promising Patient Outcomes","url":"https://stock-news.laohu8.com/highlight/detail?id=2429978585","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2429978585?lang=en_us&edition=fundamental","pubTime":"2024-04-22 22:57","pubTimestamp":1713797844,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (US) (TLSA) has released an update. Tiziana Life Sciences reports promising results from its Expanded Access Program, with 70...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tizianas-ms-drug-shows-promising-patient-outcomes?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tizianas-ms-drug-shows-promising-patient-outcomes?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2429294103","title":"Tiziana Life Sciences Announces Additional Clinical Improvements Among Multiple Sclerosis Patients in its Expanded Access Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2429294103","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2429294103?lang=en_us&edition=fundamental","pubTime":"2024-04-22 19:00","pubTimestamp":1713783600,"startTime":"0","endTime":"0","summary":"All Patients Have Either Stabilized or Improved on Nasal Foralumab Treatment and No Patients Declined in Key Clinical Measures. Gabriele Cerrone, Chairman, acting CEO and founder of Tiziana Life Sciences, commented “Fatigue is a pervasive and challenging symptom for individuals living with MS, impacting their daily lives in profound ways. The clinically meaningful improvement in fatigue levels seen in seven out of ten patients, as well as the stabilization or improvements in other key clinical outcome measures that were seen in all patients, underscores the potential of Tiziana's investigational therapy to address this critical unmet need.”Fatigue in MS, as measured via the MFIS, refers to an overwhelming sense of physical, mental, and emotional exhaustion that is disproportionate to the level of activity or effort exerted. It is a major, common, and often debilitating symptom experienced by many individuals with MS. It differs from the typical tiredness that everyone experiences from ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PPNJdkpK39wXZcwupXng.w--~B/aD0zOTY7dz01Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a70353d870d941b3824670d240516ab5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PPNJdkpK39wXZcwupXng.w--~B/aD0zOTY7dz01Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a70353d870d941b3824670d240516ab5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-announces-additional-110000681.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428465825","title":"Tiziana Life Sciences’ MS Treatment Shows Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2428465825","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2428465825?lang=en_us&edition=fundamental","pubTime":"2024-04-19 19:31","pubTimestamp":1713526273,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (US) (TLSA) has released an update. Tiziana Life Sciences has announced promising study results for their intranasal anti-CD3...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-ms-treatment-shows-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tiziana-life-sciences-ms-treatment-shows-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2428631741","title":"7 Battered Blue-Chip Stocks to Bounce From Your Portfolio This Spring","url":"https://stock-news.laohu8.com/highlight/detail?id=2428631741","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2428631741?lang=en_us&edition=fundamental","pubTime":"2024-04-19 18:20","pubTimestamp":1713522000,"startTime":"0","endTime":"0","summary":"Not all big companies are doing well in the stock market. For various reasons, these battered blue-chip stocks are struggling mightily.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/market360/2024/04/7-battered-blue-chip-stocks-to-bounce-from-your-portfolio-this-spring/","is_publish_highlight":false,"gpt_icon":0},{"id":"2428872516","title":"Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2428872516","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2428872516?lang=en_us&edition=fundamental","pubTime":"2024-04-18 23:32","pubTimestamp":1713454370,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/04/38318101/why-las-vegas-sands-shares-are-trading-lower-by-around-7-here-are-other-stocks-moving-in-thursdays-","is_publish_highlight":false,"gpt_icon":0},{"id":"2426718256","title":"Tiziana Showcases Foralumab’s Neurotherapeutic Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2426718256","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426718256?lang=en_us&edition=fundamental","pubTime":"2024-04-11 19:58","pubTimestamp":1712836680,"startTime":"0","endTime":"0","summary":"Tiziana Life Sciences (US) (TLSA) has released an update. Tiziana Life Sciences Ltd. is set to present new data on its pioneering intranasal Foralu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tiziana-showcases-foralumabs-neurotherapeutic-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tiziana-showcases-foralumabs-neurotherapeutic-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2406709747","title":"Buy Tesla Stock for Humanoid Robots and Full-Self Driving?","url":"https://stock-news.laohu8.com/highlight/detail?id=2406709747","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2406709747?lang=en_us&edition=fundamental","pubTime":"2024-01-27 04:43","pubTimestamp":1706301780,"startTime":"0","endTime":"0","summary":"If you look at the transcript of Tesla’s  last earnings call, it reads like a science fiction novel. For a second there, I had to sit back in awe of what I was witnessing. The Full-Self Driving discussion was something we used to watch in 80s movies. But then, when CEO Elon Musk started getting into details on the company’s humanoid robot product, Optimus, things really got interesting. Are we really talking about selling robots to people at scale?Somewhere between Short Circuit and Star Wars, the future has arrived.That did not translate to a bullish backdrop for the stock. Rather, sellers took control, tearing down Tesla shares from mighty heights to what’s feeling like some really bluesey lows. With so much action happening in the stock, it’s a good time to highlight it as our Chart of the Day.Moving Averages: Bartosiak starts by examining the stock's moving averages, such as the 50-day and 200-day moving averages. He points out the significance of crossovers and divergences between","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/buy-tesla-stock-humanoid-robots-204300026.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2406291400","title":"7 Over-Hyped Stocks to Sell Before They Plunge","url":"https://stock-news.laohu8.com/highlight/detail?id=2406291400","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2406291400?lang=en_us&edition=fundamental","pubTime":"2024-01-25 19:52","pubTimestamp":1706183520,"startTime":"0","endTime":"0","summary":"Maybe you’ve fallen for the hype and it's time to think about which stocks to sell. It’s easy to get excited about a stock with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/market360/2024/01/7-overhyped-stocks-to-sell-before-they-plunge/","is_publish_highlight":false,"gpt_icon":0},{"id":"2401568589","title":"BRIEF-Tiziana Life Sciences Announces Updated Clinical And Pet Scan Findings For Intranasal Foralumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2401568589","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2401568589?lang=en_us&edition=fundamental","pubTime":"2024-01-08 21:33","pubTimestamp":1704720821,"startTime":"0","endTime":"0","summary":"Jan 8 (Reuters) - Tiziana Life Sciences Ltd   :   * TIZIANA LIFE SCIENCES ANNOUNCES UPDATED CLINICAL AND PET SCAN FINDINGS FOR INTRANASAL FORALUMAB IN TWO NEW MULTIPLE SCLEROSIS PATIENTSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2401320169","title":"Tiziana Life Sciences Announces Updated Clinical and PET Scan Findings for Intranasal Foralumab in Two New Multiple Sclerosis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2401320169","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2401320169?lang=en_us&edition=fundamental","pubTime":"2024-01-08 20:00","pubTimestamp":1704715200,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 08, 2024  -- Tiziana Life Sciences Ltd. , a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced positive findings have been seen in a total of six out of eight Intermediate Size Patient Population Expanded Access  patients. These patients have shown improvements in fatigue scores measured by the Modified Fatigue Impact Scale . PET scan findings showing a reduction in microglial activation was also seen in the six patients with MFIS score improvement at the three-month evaluation period. PET scan findings for two additional EA patients  are planned to be available in late January.Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody , binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wODI5vNVbc.t4a7lu5xNtQ--~B/aD02MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0447654471f9f8d93e31cb212680cfd8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wODI5vNVbc.t4a7lu5xNtQ--~B/aD02MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0447654471f9f8d93e31cb212680cfd8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-announces-updated-120000212.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2401568546","title":"Tiziana Life Sciences to Present at Biotech Showcase Conference in San Francisco, January 8-10, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2401568546","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2401568546?lang=en_us&edition=fundamental","pubTime":"2024-01-05 22:30","pubTimestamp":1704465000,"startTime":"0","endTime":"0","summary":"NEW YORK, Jan. 05, 2024  -- Tiziana Life Sciences Ltd. , a biotechnology company developing breakthrough immunomodulation therapies, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at Biotech Showcase, San Francisco, January 8-10, 2024. The presentation will be primarily focused on the recent commencement of the phase 2 trial with intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.Presenter: Matthew Davis, MD, RPh., Chief Operating Officer and Chief Medical Officer, Tiziana Life SciencesTitle: Intranasal Anti-CD3 mAb Therapy to Enable Breakthroughs in Neuroinflammatory and Neurodegenerative DiseasesDay: Monday, January 8thTime: 9:30am PSTLocation: Roo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wODI5vNVbc.t4a7lu5xNtQ--~B/aD02MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0447654471f9f8d93e31cb212680cfd8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wODI5vNVbc.t4a7lu5xNtQ--~B/aD02MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0447654471f9f8d93e31cb212680cfd8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-present-biotech-143000684.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2401555830","title":"BRIEF-Tiziana Life Sciences Files New Patent Application for Combination Therapy of Anti-CD3 With GLP-1 Receptor Agonist","url":"https://stock-news.laohu8.com/highlight/detail?id=2401555830","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2401555830?lang=en_us&edition=fundamental","pubTime":"2024-01-05 20:09","pubTimestamp":1704456562,"startTime":"0","endTime":"0","summary":"Jan 5  - Tiziana Life Sciences Ltd   :   * TIZIANA LIFE SCIENCES FILES NEW PATENT APPLICATION FOR COMBINATION THERAPY OF ANTI-CD3  WITH GLP-1 RECEPTOR AGONIST FOR ADDITIONAL REDUCTION OF OBESITY - ASSOCIATED INFLAMMATIONSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2394042223","title":"Option Witch | Tesla Stock Still Has at Least 21% Upside - Short OTM Puts for Extra Income","url":"https://stock-news.laohu8.com/highlight/detail?id=2394042223","media":"Barchart","top":-1,"share":"https://ttm.financial/m/news/2394042223?lang=en_us&edition=fundamental","pubTime":"2023-12-28 16:02","pubTimestamp":1703750550,"startTime":"0","endTime":"0","summary":"$Tesla Inc(TLSA)$ stock still has at least 21% upside to $318 per share. This is based on its present 0.46% yield metric on next year's forecast free cash flow (FCF). We can estimate this FCF by using","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"https://www.barchart.com/story/news/22958376/tesla-stock-still-has-at-least-24-upside-based-on-its-free-cash-flow","is_publish_highlight":true,"gpt_icon":1},{"id":"2392197066","title":"Tiziana Life Sciences Doses First Patient in Phase 2a Trial of Intranasal Foralumab in Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2392197066","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2392197066?lang=en_us&edition=fundamental","pubTime":"2023-12-19 20:00","pubTimestamp":1702987200,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 19, 2023  -- Tiziana Life Sciences Ltd. , a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced “first patient dosed” in its Phase 2a study comparing two doses of intranasal foralumab and placebo in patients with non-active secondary-progressive multiple sclerosis . Six investigational centers have been recruited for this double-blind, placebo-controlled trial, with up to 18 patients per treatment arm. The primary endpoint of the trial will be the change in microglial activation based on PET scans. Clinical evaluations include the Expanded Disability Status Scale , QoL assessments, and the Modified Fatigue Impact Scale , which assess parameters that are essential to a patient’s everyday life. Novel immuno-biomarkers will be measured also and assessed for predictive relevance. Central review of PET scans and images is an integral component of this study.Activated T cells play an important role in the inflammatory process. Foralu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wODI5vNVbc.t4a7lu5xNtQ--~B/aD02MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0447654471f9f8d93e31cb212680cfd8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wODI5vNVbc.t4a7lu5xNtQ--~B/aD02MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0447654471f9f8d93e31cb212680cfd8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-doses-first-120000509.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2388396287","title":"Tiziana Life Sciences to Present at the Webull LIVE! with Corporate Connect: Biotech Investment Webinar","url":"https://stock-news.laohu8.com/highlight/detail?id=2388396287","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2388396287?lang=en_us&edition=fundamental","pubTime":"2023-12-04 20:09","pubTimestamp":1701691740,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec. 04, 2023  -- Tiziana Life Sciences Ltd. , a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that Matthew Davis, Chief Operating Officer and Chief Medical Officer will present at the Webull LIVE!with Corporate Connect: Virtual Biotech Investment Webinar on Wednesday, December 6th at 3:00 PM ET. The presentation will be focused on Tiziana’s recent clinical updates and our Phase 2 trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis  and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s disease.Webull is a leading digital investment platform built on next generation global infrastructure. The Webull Group serves tens of millions of users from over 180 countries, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/wODI5vNVbc.t4a7lu5xNtQ--~B/aD02MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0447654471f9f8d93e31cb212680cfd8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/wODI5vNVbc.t4a7lu5xNtQ--~B/aD02MDt3PTI2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/0447654471f9f8d93e31cb212680cfd8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tiziana-life-sciences-present-webull-120900670.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tizianalifesciences.com","stockEarnings":[{"period":"1week","weight":0.1713},{"period":"1month","weight":0.8707},{"period":"3month","weight":0.399},{"period":"6month","weight":0.2383},{"period":"1year","weight":-0.0306},{"period":"ytd","weight":0.393}],"compareEarnings":[{"period":"1week","weight":0.0265},{"period":"1month","weight":-0.0285},{"period":"3month","weight":0.0428},{"period":"6month","weight":0.2376},{"period":"1year","weight":0.2324},{"period":"ytd","weight":0.0693}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-  receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.083199},{"month":2,"riseRate":0,"avgChangeRate":-0.140516},{"month":3,"riseRate":0.5,"avgChangeRate":0.233864},{"month":4,"riseRate":0.5,"avgChangeRate":0.178775},{"month":5,"riseRate":0.4,"avgChangeRate":0.17461},{"month":6,"riseRate":0.4,"avgChangeRate":-0.016648},{"month":7,"riseRate":0.2,"avgChangeRate":0.308274},{"month":8,"riseRate":0.4,"avgChangeRate":-0.132125},{"month":9,"riseRate":0.2,"avgChangeRate":-0.053199},{"month":10,"riseRate":0.2,"avgChangeRate":-0.088542},{"month":11,"riseRate":0,"avgChangeRate":-0.161731},{"month":12,"riseRate":0,"avgChangeRate":-0.103326}],"exchange":"NASDAQ","name":"Tiziana Life Sciences PLC","nameEN":"Tiziana Life Sciences PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Tiziana Life Sciences PLC,TLSA,Tiziana Life Sciences PLC股票,Tiziana Life Sciences PLC股票老虎,Tiziana Life Sciences PLC股票老虎国际,Tiziana Life Sciences PLC行情,Tiziana Life Sciences PLC股票行情,Tiziana Life Sciences PLC股价,Tiziana Life Sciences PLC股市,Tiziana Life Sciences PLC股票价格,Tiziana Life Sciences PLC股票交易,Tiziana Life Sciences PLC股票购买,Tiziana Life Sciences PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Tiziana Life Sciences PLC(TLSA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Tiziana Life Sciences PLC(TLSA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}